Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.
Samuel M RubinsteinDivaya BhutaniRyan C LynchChih-Yuan HsuYu ShyrShailesh AdvaniRuben A MesaSanjay MishraDaniel P MundtDimpy P ShahR Alejandro SicaKeith E Stockerl-GoldsteinCatherine S M StrattonMatthias WeissAlicia Beeghly-FadielMelissa K AccordinoSarit E AssoulineJoy AwosikaZiad BakounyBabar BashirStephanie A BergMehmet Asim BilenCecilia A CastellanoJacob C CoganDevendra KcChristopher R FrieseShilpa GuptaDaniel HausrathClara HwangNathalie A JohnsonMonika JoshiAnup Kasi Loknath KumarElizabeth J KleinVadim S KoshkinNicole M KudererDaniel H KwonChris LabakiTahir LatifEric K C LauXuanyi LiGary H LymanRana R McKayGayathri NagarajAmanda NizamTaylor K NonatoAdam J OlszewskiHyma V PolimeraAndrew Jay PortugueseMatthew M PucPedram RazaviRachel RosovskiAndrew L SchmidtSumit A ShahAditi ShastriChristopher T SuPallawi TorkaTrisha Michel Wise-DraperLeyre ZubiriJeremy L WarnerMichael A Thompsonnull nullPublished in: Blood cancer discovery (2022)
Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.